Clinical Trials Directory

Trials / Conditions / ALL

ALL

53 registered clinical trials studyying ALL12 currently recruiting.

StatusTrialSponsorPhase
Not Yet Recruitingmy.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults
NCT07516353
Dana-Farber Cancer InstituteN/A
RecruitingA Multicenter Study of CAR-T Cells in Primary Ph+All
NCT07252336
Zhejiang UniversityPhase 2
RecruitingA Long Term Follow-up Study of TScan TCR-T Products
NCT06976736
TScan Therapeutics, Inc.
RecruitingUAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
NCT06047886
University of Alabama at BirminghamPhase 1
CompletedLong Term Safety and Efficacy of KSM-66 Ashwagandha in Adults
NCT06244147
SF Research Institute, Inc.
RecruitingPharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
NCT06131801
Children's Hospital Medical Center, Cincinnati
Active Not RecruitingUse of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childho
NCT05550948
St. Jude Children's Research HospitalN/A
RecruitingTagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
NCT05476770
Therapeutic Advances in Childhood Leukemia ConsortiumPhase 1
Unknowncommd7 Gene Expression in ALL
NCT05592470
Assiut University
WithdrawnPatient Satisfaction in the Orthopedic Surgery Clinic
NCT04343027
NYU Langone HealthN/A
RecruitingInotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
NCT05940961
Sheng-Li Xue, MDPhase 2
UnknownMultiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
NCT05414162
University Hospital, Bonn
Active Not RecruitingVenetoclax Plus Inotuzumab for B-ALL
NCT05016947
Dana-Farber Cancer InstitutePhase 1
UnknownACL Reconstruction With/Without ALL Reconstruction
NCT05461625
Centre of Postgraduate Medical EducationN/A
RecruitingOptical Genome Mapping in Hematological Malignancies
NCT05009537
University Hospital, Brest
RecruitingCord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
NCT04644016
Memorial Sloan Kettering Cancer CenterPhase 2
UnknownGNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
NCT04601584
AO GENERIUMPhase 1 / Phase 2
CompletedHaplo Peripheral Blood Sct In GVHD Prevention
NCT04473911
Zachariah Michael DeFilippPhase 1
UnknownRisk of Osteoarthritis of the Knee at Least 5 Years After ACL Reconstruction: Comparative Study Between an Iso
NCT05123456
Ramsay Générale de SantéN/A
RecruitingRuxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
NCT03571321
University of ChicagoPhase 1
RecruitingA Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Tr
NCT03739502
University of RochesterPhase 2
CompletedHaploidentical Donor vs mMUD in Hematological Malignancies
NCT03275636
DKMS gemeinnützige GmbHPhase 2 / Phase 3
TerminatedUse of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders
NCT03198234
Roncarolo, Maria Grazia, MDPhase 1
CompletedFamily History in a Singaporean Healthy Population
NCT03114553
Duke University
Active Not RecruitingProject Baseline Health Study
NCT03154346
Baseline Study LLC
RecruitingAmish/Mennonite Research Contact Registry
NCT02990572
University of Pittsburgh
UnknownPonatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia
NCT02776605
PETHEMA FoundationPhase 2
TerminatedPharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Ac
NCT02795520
OncoTherapy Science, Inc.Phase 1 / Phase 2
UnknownCollaborative Network to Take Responsibility for Oral Anticancer Therapy
NCT02861209
KU LeuvenN/A
CompletedAnti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing
NCT02315612
National Cancer Institute (NCI)Phase 1
CompletedPhotochemotherapy and Graft-versus-leukemia in Acute-leukemia
NCT02631993
Karolinska University Hospital
CompletedPrediction of Excretion and Toxicity of High Dose Methotrexate in Children and Adolescents With ALL
NCT02133599
Ann & Robert H Lurie Children's Hospital of ChicagoN/A
CompletedMassage Therapy Versus Music Therapy Pilot Study
NCT02227680
Boston Medical CenterN/A
CompletedUnderstanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood
NCT02528435
University of Aarhus
CompletedAnti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
NCT01593696
National Cancer Institute (NCI)Phase 1
TerminatedA Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
NCT01532635
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityPhase 2
CompletedPOETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
NCT01319864
Seattle Children's HospitalPhase 1
TerminatedRituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
NCT01230788
Emory UniversityN/A
CompletedPhase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
NCT01204164
Tragara Pharmaceuticals, Inc.Phase 1
CompletedPilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
NCT01012492
Boston Children's HospitalPhase 2
CompletedAllogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients
NCT00863148
Nantes University HospitalPhase 2
CompletedA Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic
NCT00964873
Synta Pharmaceuticals Corp.Phase 1
CompletedUmbilical Cord Blood Transplant for Hematological Malignancies
NCT00891592
University of PennsylvaniaPhase 1
UnknownFeasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT)
NCT00815568
Samsung Medical CenterPhase 2
TerminatedMyeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Gr
NCT00814983
Duke UniversityPhase 1 / Phase 2
CompletedLow Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
NCT00539695
Baylor College of MedicinePhase 2
TerminatedRapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies
NCT00776373
Abramson Cancer Center at Penn MedicinePhase 1 / Phase 2
CompletedTesting the Re-Engineered Hospital Discharge
NCT00252057
Boston UniversityN/A
CompletedCD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
NCT00333190
Dana-Farber Cancer InstituteN/A
CompletedNonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of He
NCT00533923
Beth Israel Deaconess Medical CenterPhase 2
CompletedPilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic
NCT00013533
National Cancer Institute (NCI)EARLY_Phase 1
CompletedNonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
NCT00636909
Beth Israel Deaconess Medical CenterPhase 2
CompletedUnrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders
NCT00511537
University of California, San Francisco